spacer
home > ebr > winter 2002 > target validation in the nervous system using herpes simplex viral vectors
PUBLICATIONS
European Biopharmaceutical Review

Target Validation in the Nervous System using Herpes Simplex Viral Vectors

The recent sequencing of the human genome has produced a plethora of potential novel drug targets and candidate genes for gene therapy. New drug discovery using large-scale functional genomics approaches, however, faces the major problem of target validation. Traditionally this has been achieved by pharmacology, using specific antagonists and agonists, or by using transgenic animals, particularly knock-out mice. However, these approaches have considerable drawbacks, being extremely time-consuming, laborious and expensive. This is particularly the case if large numbers of potential target genes are to be tested.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Dr James Palmer, Senior Scientist, and Dr Robert Coffin, Chief Scientific Officer, at BioVex Ltd Dr James Palmer joined BioVex Ltd, a gene delivery and therapeutic vaccine company, in September 1999. He was previously a post-doctoral fellow at University College London in the academic laboratory of BioVex's Founding Scientist and current Research Director, Dr Robert Coffin.
Dr Palmer is currently a Senior Scientist developing herpes simplex viral vector systems for gene delivery to the nervous system for target validation purposes. Prior to this, he obtained his PhD in Molecular Neuroscience from the University of Cambridge working in the Neurobiology Division of the MRC Laboratory of Molecular Biology, and his BSc in Pharmacology from the University of Bristol.

Dr Robert Coffin is a Founding Scientist at Biovex Ltd, Lecturer in Virology and Gene Therapy at University College London (UCL) and Honorary Senior Lecturer at The Institute of Child Health. Following a PhD in Virology at Imperial College, Dr Coffin moved to UCL to develop herpes simplex virus (HSV) based vectors and to study the molecular basis of HSV latency.

During the course of this work - which led to the foundation of Biovex Ltd where he is CSO - vectors were developed that are useful for studying, and potentially treating, neurological disease and for the immune-based treatment of various diseases. Dr Coffin is a world recognised expert in the field of HSV vectorology and latency, and has authored numerous scientific publications.


spacer
Dr James Palmer
spacer
spacer
spacer
Dr Robert Coffin
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Sustainability, plastics and Brexit: Keynote speakers set to inspire at PPMA Total Show 2019

Experts from IKEA, the British Plastics Federation and The Sunday Times to create a forum for education, knowledge-sharing and debate
More info >>

White Papers

Contemporary Issues in Comparator Trial Supply

Clinigen CTS

As trial design and execution becomes ever-more complex, initiatives to adapt, increase efficiency and control costs without compromising quality become paramount. Here, Clinigen CTS covers the broad issues and summarises the responses our industry is making in this increasingly demanding landscape.
More info >>

 
Industry Events

Nordic Life Science Days 10/12 September 2019

10-12 September 2019, Malmo Sweden

Nordic Life Science Days is the largest Nordic partnering conference for the global Life Science industry. Bringing together the best talents in Life Science, offering amazing networking and partnering opportunities, providing inputs and content on the most recent trends. Nordic Life Science Days attracts leading decision makers from the Life Science sector, not only from biotech, pharma and medtech but also from finances, research, policy and regulatory authorities.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement